PMID- 14533978
OWN - NLM
STAT- MEDLINE
DCOM- 20040510
LR  - 20151119
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 106
IP  - 2
DP  - 2004 Feb
TI  - A feeling in the waters: diagnosis of heart failure using urinary natriuretic 
      peptides.
PG  - 111-2
AB  - Plasma levels of brain natriuretic peptide (BNP) and N-terminal pro-BNP (N-BNP) 
      are highly sensitive markers of ventricular dysfunction and/or hypertrophy and, 
      in established disease, offer prognostic value and may be useful for guidance of 
      therapy. Ng and co-workers report in this issue of Clinical Science that urinary 
      levels of N-BNP may be as useful as plasma levels for the discrimination of 
      patients with and without heart failure. This raises the potential for a 
      relatively simple urine test that could be used for the diagnosis of heart 
      failure. Roles in prognostication and the guidance of therapy may also be 
      possible but, perhaps of most significance, measurement of urinary N-BNP may be 
      applied to screening of patients at high risk of heart failure. The main 
      limitations of the study were that the sample of heart failure patients comprised 
      only 34 individuals with New York Heart Association functional Class IV and that 
      the observed correlation between levels of urinary N-BNP and plasma creatinine 
      seemed counter-intuitive. The latter issue needs clarification, as renal 
      impairment is a frequent co-morbidity among patients with heart failure and will 
      potentially confound any observed association between ventricular dysfunction and 
      urinary N-BNP levels. Another caveat is that it is unclear if testing for urinary 
      N-BNP can be cheaply and conveniently administered on a large scale. 
      Nevertheless, this first demonstration of elevated N-BNP in the urine of patients 
      with heart failure raises a number of exciting possibilities with regard to the 
      management of patients with established or possible heart failure. Further 
      investigation is required and eagerly awaited.
FAU - Krum, Henry
AU  - Krum H
AD  - NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of 
      Epidemiology and Preventive Medicine, Monash University Central and Eastern 
      Clinical School, Alfred Hospital, Melbourne, Victoria, Australia. 
      henry.krum@med.monash.edu.au
FAU - Liew, Danny
AU  - Liew D
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Biomarkers)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
CON - Clin Sci (Lond). 2004 Feb;106(2):129-33. PMID: 13678415
MH  - Biomarkers/urine
MH  - Comorbidity
MH  - Creatinine/blood
MH  - Heart Failure/blood/*diagnosis/urine
MH  - Humans
MH  - Natriuretic Peptide, Brain
MH  - Nerve Tissue Proteins/*urine
MH  - Peptide Fragments/*urine
MH  - Predictive Value of Tests
MH  - Renal Insufficiency/blood/urine
EDAT- 2003/10/10 05:00
MHDA- 2004/05/11 05:00
CRDT- 2003/10/10 05:00
PHST- 2003/10/09 00:00 [accepted]
PHST- 2003/10/08 00:00 [received]
PHST- 2003/10/10 05:00 [pubmed]
PHST- 2004/05/11 05:00 [medline]
PHST- 2003/10/10 05:00 [entrez]
AID - CS20030330 [pii]
AID - 10.1042/CS20030330 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2004 Feb;106(2):111-2. doi: 10.1042/CS20030330.